in vivo DNA, si/miRNA transfection
- Polyvalent: in vivo delivery of DNA, si/sh/miRNA in any animal model
- Easy to use: two-step protocol
- Renowned: Most advanced in vivo transfection technology with over 700 peer-reviewed publications
- Successful: Used from fundamental research to Human clinical trials
in vivo functional studies (overexpression, knock-down, CRISPR genome editing)
Various systemic and local administration routes
|Number of transfections|
eg. 100 µl of in vivo-jetPEI® delivery reagent is sufficient to perform 15 to 25 intravenous injections in mouse.
-20 ± 5 °C, for at least 12 months
10% glucose solution
in vivo-jetPEI® is the most advanced in vivo transfection reagent for safe and efficient in vivo delivery of DNA, si/RNA and other oligonucleotides in animal models. With a track record of over 700 publications, in vivo-jetPEI® is the consensual in vivo transfection method for in vivo functional studies, cancer research and immunization/vaccination.
Table 1: Range of in vivo-jetPEI® quality grade reagents for each step of in vivo DNA, si/miRNA transfection. in vivo-jetPEI® is available as an R&D grade for fundamental research and proof of concept studies. For preclinical biodistribution and toxicology studies and early phase clinical studies, we supply a higher preclinical grade in vivo-jetPEI®. GMP in vivo-jetPEI® is the highest quality grade available to meet quality demands in Human clinical trials.
|Reference Number||Amount of reagent||Amount of 10% glucose solution|
|201-10G||0.1 ml||10 ml|
|201-50G||0.5 ml||2 x 10 ml|
Polyvalent: in vivo delivery of DNA, si/sh/miRNA nucleic acid in any animal model including mice
The easiness of use and versatility of in vivo-jetPEI® allows scientists to perform gene function studies by overexpressing or downregulating a gene in any organ/tissue of interest. in vivo-jetPEI® is polyvalent: it is suitable for the delivery of nucleic acid (plasmid DNA, siRNA, shRNA, miRNA and oligonucleotides) in any animal model (mice, rat, guinea pig, dog, rabbit, monkey, etc…). Numerous Scientific publications demonstrate the successful delivery of each type of nucleic acid in different animal model.
in vivo-jetPEI® has already been used to target a wide range of organs by systemic and local injection routes. Local administration routes include subcutaneous tumor, intracerebral or intra-articular injections and topical application. The injection route largely determines the targeted organs. For example, upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery. Conversely, upon intraperitoneal injection, the gene of interest will be expressed in the ovary, pancreas, diaphragm, uterus and stomach (Fig. 1). To achieve organ specific gene expression, cell-specific promoters can be combined with the choice of a local injection route to restrict gene expression to an organ/tissue. Guidelines for systemic and most local injection routes are available.
Easy-to-use: two-step protocol
in vivo-jetPEI® is the reagent of choice to deliver DNA, si/sh/miRNA nucleic acid using most systemic and local injection routes. The protocol is easy to use and similar to a classical in vitro transfection: the nucleic acid and in vivo-jetPEI® reagent are mixed and directly injected into the animal model (Fig. 2).
Our delivery experts are available to adapt your protocol to your animal model and send you the relevant literature.
Renowned: Most advanced in vivo delivery technology for cancer research, immunization and vaccination
in vivo-jetPEI® is a powerful polymer-based reagent with unique properties. In the provided complexation solution, in vivo-jetPEI® condenses any nucleic acid into stable nanoparticles of ca. 50 nm diameter (Fig 1). These nanoparticles are sufficiently small to efficiently diffuse within tissues and enter cells by endocytosis, while protecting naked nucleic acids from degradation. At the cellular level, in vivo-jetPEI facilitates both endosomal escape using the proton sponge mechanism (Akinc et al. (2005), J Gene Med 7: 657), and crossing of the nuclear membrane (Brunner et al. (2002), Mol Ther 5: 80).
Successful: Used from fundamental research to Human clinical trials
Due to its reliability, in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. There are currently several ongoing clinical trials for cancer therapies, vaccination and immunization using higher quality grade GMP in vivo-jetPEI®.
in vivo functional studies
in vivo-jetPEI® is perfectly suited to study gene function in vivo and provides the easiest method for the validation of in vitro functional studies into animals.
in vivo-jetPEI®-based nucleic acid delivery is now widely used for tumor growth inhibition studies. As an example, the delivery of a modified siRNA against Cyclin B1 with in vivo-jetPEI® inhibits the formation of lung metastases (Fig. 4A) and in vivo-jetPEI® mediated delivery of a modified siRNA against Survivin prevents the growth of a tumor xenograft model (Fig. 4B).
Following in vivo administration of plasmid DNA formulated with in vivo-jetPEI®, the expressed protein can elicit the induction of a robust and persistent immune response, hence protecting animals from different viruses or pathogens challenge.
in vivo gene editing using CRISPR/Cas9 system
in vivo-jetPEI®-mediated delivery of CRISPR/Cas9 system targeting tumor suppressor genes provides a flexible and effective method to investigate somatic loss-of-function alterations and their influence on tumorigenesis.
in vivo-jetPEI® is the leading in vivo delivery method with a proven track record of peer-reviewed scientific publications, ranging from fundamental gene function studies to cancer research and vaccination studies. Here is a list of recent publications per application:
- Cancer research:
Guo, Shixiang & Fesler, Andrew & Huang, Wenjie & Wang, Yunchao & Yang, Jiali & Wang, Xianxing & Zheng, Yao & Hwang, Ga-Ram & Wang, Huaizhi & Ju, Jingfang. (2019). Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Molecular Therapy – Nucleic Acids.
Chen, C. H., Chen, P. Y., Lin, Y. Y., Feng, L. Y., Chen, S. H., Chen, C. Y., Huang, Y. C., Huang, C. Y., Jung, S. M., Chen, L. Y., Wei, K. C. (2019). Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma., J Neurosurg , 1-12
Choe, M. H., Yoon, Y., Kim, J., Hwang, S. G., Han, Y. H., Kim, J. S. (2018). miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP., Cell Death Dis 9, 640
Lee, J., Park, E. B., Min, J., Sung, S. E., Jang, Y., Shin, J. S., Chun, D., Kim, K. H., Hwang, J., Lee, M. K., Go, Y. Y., Kwon, D., Kim, M., Kang, S. J., Choi, B. S. (2018). Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies., Nucleic Acids Res 46, 1635-1647
O’Neil, R. T., Saha, S., Veach, R. A., Welch, R. C., Woodard, L. E., Rooney, C. M., Wilson, M. H. (2018). Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo., Nat Commun 9, 1325
Cao, W., Mishina, M., Amoah, S., Mboko, W. P., Bohannon, C., McCoy, J., Mittal, S. K., Gangappa, S., Sambhara, S. (2018). Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet or in vivo-jetPEI((R)) induces enhanced serological, cellular and protective immune responses., Drug Deliv 25, 773-779
- Functional studies:
Vanpouille-Box, C., Hoffmann, J.A. & Galluzzi, L. (2019). Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles. Nat Rev Drug Discov 18, 845–867
Xiao, Y., Barbosa, C., Pei, Z., Xie, W., Strong, J. A., Zhang, J. M., Cummins, T. R. (2019). Increased resurgent sodium currents in Nav1.8 contribute to nociceptive sensory neuron hyperexcitability associated with peripheral neuropathies., J Neurosci
Fujita, K., Chen, X., Homma, H., Tagawa, K., Amano, M., Saito, A., Imoto, S., Akatsu, H., Hashizume, Y., Kaibuchi, K., Miyano, S., Okazawa, H. (2018). Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology., Nat Commun 9, 433
Wen, Q., Wu, S., Lee, W. M., Wong, C. K. C., Lui, W. Y., Silvestrini, B., Cheng, C. Y. (2019). Myosin VIIa supports spermatid/organelle transport and cell adhesion during spermatogenesis in the rat testis., Endocrinology.
« I finished the experiments and I think in vivo-jetPEI® works great. I am very pleased with the results. Actually some of the work we have done with in vivo-jetPEI® as well as jetSI™ 10 mM has been published in Science. […] I am also very pleased with the technical assistance. Many thanks! » – Emine E.K., Hacettepe University, Turkey
« Our project is going quite well, we are working a lot with your siRNAs delivery system, and we are obtaining superb results in vivo. » – Mattia C., L’Aquila University, Italy
« in vivo-jetPEI® is a very nice reagent to work with! » – Marie-Line G., Lady Davis Institute, Canada
Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.
Each batch of in vivo-jetPEI® reagent is tested for conformity to established Quality Controls and relevant specifications. A Certificate of Analysis is provided with each vial of reagent